Related Experiment Video
Updated: Jul 9, 2026

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
Published on: May 4, 2012
[Advances in the study of expression and regulation of P-glycoprotein]
1State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China.
Abstract:
Resistance to the cytotoxic actions of antineoplastic drugs remains a barrier to the establishment of curative chemotherapy regimens for cancer. Over-expression of P-glycoprotein (P-gp), encoded by the MDR1 gene is the major molecular mechanism enhancing efflux pump for various anticancer agents, hence caused MDR. Transcription factor, DNA methylation, histone acetylation/deacetylation, phosphorylation and glycosylation and MDR1 gene polymorphisms play pivotal role in regulation of P-glycoprotein, and may become new therapeutic targets. This paper summarized the advances of studies on expression and regulation of P-glycoprotein.
Insights
Drug resistance in cancer chemotherapy is often caused by P-glycoprotein (P-gp) over-expression. Understanding P-gp regulation offers new therapeutic targets to overcome multidrug resistance (MDR) and improve cancer treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer chemotherapy faces a significant hurdle in drug resistance.
- Over-expression of P-glycoprotein (P-gp), encoded by the MDR1 gene, is a primary mechanism for this resistance.
- P-gp acts as an efflux pump, reducing the intracellular concentration of various anticancer drugs.
Purpose of the Study:
- To summarize recent research on the expression and regulation of P-glycoprotein.
- To identify potential therapeutic targets for overcoming multidrug resistance (MDR).
Main Methods:
- Review of studies on P-glycoprotein expression.
- Analysis of regulatory mechanisms influencing P-glycoprotein levels.
Main Results:
- P-glycoprotein over-expression is a key factor in multidrug resistance.
- Several factors, including transcription factors, epigenetic modifications (DNA methylation, histone acetylation/deacetylation), post-translational modifications (phosphorylation, glycosylation), and MDR1 gene polymorphisms, regulate P-gp expression.
Conclusions:
- P-glycoprotein plays a critical role in anticancer drug resistance.
- The regulatory mechanisms of P-glycoprotein present promising new targets for therapeutic intervention to enhance chemotherapy efficacy.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Protein Glycosylation
Glycosylation occurs in...
Proteoglycans
GPCRs Regulate Adenylyl Cylase Activity
Two...
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
GPI Anchoring of Proteins in the ER Membrane
GPI-anchor structure
A sequence of 11 enzymatic reactions results in the synthesis of the complete GPI anchor consisting of a hydrophobic and a hydrophilic portion. The hydrophobic portion comprises phosphatidylinositol, while the hydrophilic part comprises polar groups like phosphoethanolamine,...

